Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

In one study, once-daily danuglipron resulted in one patient who experienced drug-related elevated liver enzymes.

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

Goldman Sachs launched its coverage of Viking Therapeutics (NASDAQ:VKTX) with a Neutral recommendation and a $30 per share target on Tuesday, arguing that competitive headwinds in the weight loss drug ...

While it is understood that the drugs have also proven to be safe and effective for thousands, the negative issues have led ...

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Linda Gigliotti, MS, RDN, CDCES, FAND, about combining the use of GLP-1 ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

COPENHAGEN, Denmark I April 2, 2025 I Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

a triple agonist of the receptors for GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon, which is early-stage development for the treatment of obesity, type 2 diabetes ...